SOST and hyperostosis corticalis generalisata: Although research on the cellular and molecular mechanisms of sclerosteosis and van Buchem disease guided the development of anti-sclerostin antibody to treat osteoporosis, an osteocyte function-targeted therapy for sclerosteosis and van Buchem disease has not yet been developed.